^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    14h
    Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF V600
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib)
    16h
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    18h
    KRASCENDO 3: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Hoffmann-La Roche
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • divarasib (RG6330)
    19h
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    19h
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=300, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=117 --> 300
    Enrollment open • Enrollment change
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    20h
    PRIMAVERA: AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. (clinicaltrials.gov)
    P1/2, N=161, Recruiting, AstraZeneca | N=110 --> 161 | Trial completion date: May 2026 --> Apr 2029 | Trial primary completion date: May 2026 --> Apr 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    21h
    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine
    23h
    Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    Endometrial Neuroendocrine Carcinoma With Widespread Metastases: Diagnostic and Therapeutic Challenges in a Rare Malignancy. (PubMed, Cureus)
    She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Histopathology confirmed small-cell NEC with squamous differentiation; expert review favored a poorly differentiated/dedifferentiated endometrial carcinoma with neuroendocrine and squamoid features. This case illustrates an atypical initial presentation with neurologic deficits from spinal metastases, emphasizing the need for prompt recognition and multidisciplinary management.
    Journal • PD(L)-1 Biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • etoposide IV
    1d
    C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab. (PubMed, Kidney Med)
    Despite treatment with corticosteroids, plasma exchange, cyclophosphamide and eculizumab he remained dialysis-dependent. PD-1 inhibitors, such as pembrolizumab, are known to predispose to loss of tolerance and generation of autoantibodies. In this case, factor B autoantibodies were detected in association with C3GN.
    Journal
    |
    CFB (Complement Factor B)
    |
    Keytruda (pembrolizumab) • cyclophosphamide
    1d
    Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy for Resectable NSCLC: Case Report. (PubMed, Respirol Case Rep)
    We report a 69-year-old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic-assisted lobectomy. He received adjuvant pembrolizumab and daratumumab-CyBorD with partial hematologic response. This case highlighted that amyloid can unexpectedly be a second diagnosis after post-neoadjuvant lung resections and that proteomic subtyping is essential for prompt haematologic staging and treatment.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTPRT (Protein tyrosine phosphatase receptor type T)
    |
    TP53 mutation • TMB-H
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Darzalex (daratumumab)
    1d
    ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Stephen Shiao | Trial completion date: Dec 2032 --> Jul 2033 | Initiation date: Sep 2025 --> Jun 2026 | Trial primary completion date: Dec 2032 --> Jul 2033
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)